Compare Johnson & Johnson (JNJ) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Impinj Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Impinj Inc trades at $189.56 (market cap $5.60B). The key difference: Johnson & Johnson is far larger — about 110.4× Impinj Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Impinj Inc for 22 Days on average.
| JNJ | PI | |
|---|---|---|
Market Cap | $618.09B | $5.60B |
Volume | 6,050,983 | 9,929 |
Sector | Health | Technology |
52-Week High | $278.43 | $241.91 |
52-Week Low | $186.00 | $91.34 |
Typical Hold Time | 129 Days | 22 Days |
Enterprise Value | $646.37B | $5.73B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Impinj (PI) trades at $189.16, down 0.98% on the day, with strong analyst support (16 buy ratings, 0 sell) and a consensus price target of $178.83. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though profitability remains negative with a -7.26% net income margin. Recent news highlights include upcoming Q3 earnings and CFO stock sales.
While technical indicators and analyst sentiment are positive, fundamental challenges persist with negative ROE and high valuation multiples. The company's RAIN RFID technology presents growth opportunities in logistics, but investors should weigh execution risks against the bullish consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
